MARKET WIREYahoo • 1d ago
Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks — But Pares Stake In This Pharma Giant That Had A Blowout Q3Ark Invest increased its exposure to several widely followed biotechnology stocks during the session.
Why TEM Stock advanced +1.61% Today — RQD Quant Desk Flash
$77.84 +1.61% NASDAQ • Public Delayed / 60s Snapshot
Tempus AI Inc. (TEM) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C- • HOLD / WATCH
Cap $14.13B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+0.4% Base Target
WHALE OPTIONS TUG-OF-WAR:54% Call Buyers ($2.4M)
46% PutsMax Pain: $76.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TEM Stock advanced +1.61% Today — RQD Quant Desk Flash
Tempus AI Inc. (TEM) advanced +1.61% to $77.84 as options desks priced 54% call premium vs. 46% put protection around the $76 max-pain magnet. Solid 62% profit margin (-18% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 74% of its 52-week range ($40.77 – $90.53) with RSI-14 at 51.9 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $2.4M in bullish call flow vs. $2.1M in put flow (Put/Call 0.85x, implied earnings swing ±7.6%).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 44% gross margin and $0 annual free cash flow.
Live TEM Headlines & Catalysts
CATALYSTYahoo • 1d ago
Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AIDublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Clinical Genomics Interpretation Platforms Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global clinical genomics interpretation platforms
CATALYSTYahoo • 1d ago
Clinical Genomics Sequencing, Biobank, and Database Services Global Market to 2035 | Capitalize on AI and Precision Medicine: Illumina, Thermo Fisher, BGI Genomics, Tempus AIBoost ROI by scaling commercial services, integrating AI and secure cloud genomics, forming data partnerships, expanding into emerging markets, and using tiered pricing and account-based marketing.Dublin, Oct. 30, 2026 (
CATALYSTYahoo • 1d ago
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?Tempus AI or Doximity: Which medical information systems stock offers better value? Compare growth prospects, AI expansion, earnings estimates and valuation.
MARKET WIREYahoo • 2d ago
This Stock Offers Juicy Option Premiums, But Also Is Highly RiskyImplied volatility currently sits at 87%, close to the highest levels for Tempus AI stock in the last 12 months.
CATALYSTYahoo • 3d ago
IPO Edge NYSE Firesides Scheduled for Dec 7IPO Edge and CorpGov will be conducting interviews from the floor of the New York Stock Exchange on Dec. 7, 2026. We invite guests to join 15-minute fireside chats recorded in a […]
CATALYSTYahoo • 3d ago
Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks RallyKey TakeawaysAbsci rose 12% today, Schrödinger 11% and Recursion 9%, and no company news explains any of the three moves. Schrödinger’s rally has the most business behind it, and Absci’s rally is mostly about investors’
CATALYSTYahoo • 3d ago
Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to DeclineSchrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MARKET WIREYahoo • 4d ago
Can You Still Buy Tempus AI Stock Today?For questions about this article or underlying research, email help@trefis.com.
MARKET WIREYahoo • 4d ago
Tempus AI (TEM) Could Be 5% Undervalued After Bristol Myers And Pathos DealsTempus AI (TEM) just deepened its ties with Bristol Myers Squibb and Pathos AI, securing long-term data licensing deals that spotlight its role in real-world oncology and neuroscience datasets. Tempus AI has been volatil
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live TEM Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
TEM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.17%▲ ASCENDING CHANNEL
2026-10-30O $73.26H $76.65L $70.84C $72.22VOL 10.43M
RES: $98.61SUP: $63.55SMA50: $70.69SMA200: $56.94
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TEM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
25.5%/yr Implied 5Y Growth
vs. +83.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TEM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TEM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TEM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
TEM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TEM stock moving today?
Why TEM Stock advanced +1.61% Today — RQD Quant Desk Flash. Solid 62% profit margin (-18% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.